Research
Hormonal
GLP-1 receptor ligands improve bone health and reduce fracture risk in type 2 diabetes, with clinical outcomes varying by specific agent.
If you have type 2 diabetes, some GLP-1 drugs like liraglutide and lixisenatide may help protect your bones and reduce fracture risk. However, not all GLP-1 drugs have this effect (e.g., exenatide shows no impact). Discuss your bone health history with your doctor to choose the right medication.
ModerateQualifiesMEDIUM confidence
In the clinic, recent reports show exenatide to have no impact on bone fractures, whilst lixisenatide and liraglutide reduce fracture occurrence... Diabetic animal models present with a loss of bone mineral density which can be restored through administration of GLP-1R mimetics
Why this rating
Based on animal models and mixed clinical trial results (some show benefit, others no impact).
Source
Metabolic responses and benefits of glucagon‐like peptide‐1 (GLP‐1) receptor ligands
Neil Tanday et al. · British Journal of Pharmacology · 2021
DOI 10.1111/bph.15485
narrative_reviewCited 39×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor ligands reduce cardiovascular mortality and major adverse cardiovascular events in patients with type 2 diabetes, with efficacy varying by specific drug half-life and homology to native GLP-1.Strong
- GLP-1 receptor activation suppresses glucagon secretion primarily through an indirect mechanism involving somatostatin release from delta-cells, rather than direct action on alpha-cells.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →